Form 8-K · Current Report · Filed 2026-02-03
Amgen Discloses 2025 Earnings and Non-GAAP Financial Measures
On February 3, 2026, Amgen Inc. announced its unaudited financial results for the fourth quarter and full year of 2025. The company reported non-GAAP financial measures including earnings per share, operating income, and expenses, adjusted for acquisition-related expenses, restructuring costs, and other items. These non-GAAP measures are provided to enhance understanding of the company's performance and facilitate comparisons with past periods.
- Filer
- Amgen Inc. AMGN · NASDAQ
- Filed
- Accession
- 0000318154-26-000003
- CIK
- 0000318154
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$344.68
Next session
+6.2%
Since filing
+11.7%
Latest close
$385.16
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from AMGN reporting the same item, with the next session's move:
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Never miss another AMGN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.